首页 上巨实业医疗(usHOLX)-基本信息

上巨实业医疗(usHOLX)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:74.12

最高价:75.62

成交量:834826.0

昨收价:73.82

最低价:73.93

最新价:74.48

行情图标
概要信息

中文名称:上巨实业医疗


英文名称:Hologic


行业:医疗


简介:Hologic, Inc.于1985年10月在美国马萨诸塞州成立,并于1990年3月在美国特拉华州重新合并成立


电话:1-508-2632900


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Hologic,豪洛捷,在美国和全球开发、生产并销售诊断产品、医疗成像系统以及妇女外科检查产品,是全球分子诊断公司前三强(分别是:罗氏、Illumina和Hologic)。豪洛捷在为女性健康服务的九个技术领域中占据着世界第一的位置,包括:乳腺癌的诊断与治疗、宫颈癌筛查、产前检测和骨质疏松症检测。Hologic公司分4个部门来运作:诊断,乳房保健,妇科手术和骨骼健康。 诊断部门——提供APTIMA家庭实验、目标捕获/核酸提取技术、转录介导的扩增技术、杂交保护和双动力学分析、仪器仪表、化学侵略者平台、新柏氏系统、胎儿纤维连接蛋白测试、家庭的Procleix试验、病毒学和传染病产品等。 乳房健康部门——提供乳腺影像以及相关产品和配件,包括数字和胶片为基础的乳房X光检查系统;计算机辅助检测(CAD)的乳腺影像系统;乳腺活检(活体组织检查)设备;乳腺活检部位标记及引导系统;乳房近距离放射治疗产品;乳房X光检查二维和三维图像采集和显示系统;C-视图;感光涂料。 妇科手术部门——提供NovaSure系统,治疗妇女子宫异常出血;MyoSure系统,宫腔镜切除肌瘤;豪洛捷经临床验证的产品组合提供有助于检测和防止宫颈癌所必备的工具, 配合使用时,ThinPrep® 新柏氏涂片检查、ThinPrep 成像系统和 Cervista® HPV 检测可帮助您识别宫颈癌高危女性,以便您和您的患者做出明智决定,使宫颈癌筛查变得更加智能。 骨骼健康部门——提供horizon X-ray系统骨密度计(如:Hologic Sahara超声骨密度仪)的开发,来对骨折部位以及骨密度进行评估和检测;迷你C臂成像系统来执行对一个患者的四肢的微创外科手术,如手,腕,膝,脚和踝关节。此外,豪洛捷还提供实验室设备。豪洛捷一直致力于为实验室提供最新、最有效的技术以及一流的客户服务。 其ThinPrep® 新柏氏涂片检查从10年前开始就0掀起了新柏氏涂片检查的革命,今天,其ThinPrep 新柏氏影像分析系统日渐成为新的医疗标准。ThinPrep 新柏氏影像分析系统应用计算机技术,自动扫描每一个细胞和细胞簇,并突出显示关注区以便进行人工分析。 这一将计算机影像技术与人类经验相结合的双重阅片技术改进了筛查效果,同时将人工判读技能集中到那些仅凭计算机分析难以解释的区域:那些最值得关注的细 胞。Cellient® 自动细胞块系统是第一个完全自动化的细胞块系统。 真空辅助过滤将凝集细胞块中的可用细胞, 产生可用于有效检查的具有诊断意义的高质量细胞块 - 整个过程不到一小时。上巨实业医疗(豪洛捷)Hologic公司,通过直销、独立分销商和销售代表网络来销售其产品,与Quest Diagnostics公司结成战略联盟。豪洛捷Hologic(HOLX)大事记: 1985年,首获FDA批准使用DNA探针技术进行临床诊断测验,在美国推行第一代产品,即支原体组织培养试验。 1987年,完成首次公开筹股(IPO),筹集款项1,620万美元。 1988年,正式推出PACE®检测试剂,这是针对两种流行的性传播疾病,即CT和GC的第一代检查设备。 1989年,因核糖体核糖核酸(rRNA)检验方法获得首个美国专利标章,该项技术也是Gen-Probe之本。获FDA批准销售首批的四种AccuProbe培养认证检测试剂。 1994年,在美国推出四种产品:甲类链球菌直接检测试剂(GASDIRECT®)、CT和GC的PACE® 2组合检测试剂、CT的探针竞争确证检测试剂和GC的探针竞争确证检测试剂。 1995年,专有DNA序列扩增技术被授予美国专利,推出TMA(转录介导的扩增技术)。 1996年,在美国正式推出AMPLIFIED结核分枝杆菌复合群核酸检测试剂(TMA杂交法) ®;FDA首次批准的检验结核分枝杆菌的核酸扩增技术。 2001年,FDA批准销售APTIMACombo 2® 测定。 2002年,FDA批准将Gen-Probe研发的 PROCLEIX® 试剂用于血库同步检验人体免疫缺陷病毒1型 (HIV-1) 和丙型肝炎病毒(HCV)。正式推出DTS® 800系统,将其应用APTIMA Combo 2® 试剂中,进行自动化处理。 2003年,收购MLT公司(MLT所研发的技术是Gen-Probe化学发光杂交保护测定(HPA)检验技术的基础)。FDA批准使用Gen-Probe研发的完全自动化的TIGRIS® DTS® 系统进行性传播疾病检验。批准TIGRIS系统运行APTIMA COMBO 2®试剂。 2005年,FDA批准APTIMA® 试剂上市许可,检测淋病奈瑟氏菌(GC)。授予美国上市许可,使用APTIMA Combo 2® 测定检验经Cytyc's ThinPrep® 2000系统收集和处理的液体巴氏样品中所含沙眼衣原体和淋病奈瑟氏菌。布什总统授予Gen-Probe 2004年度国家技术创新领域最高荣誉——美国国家技术奖,以表彰Gen-Probe在研发创新性核酸测定领域的创举,得以确保国家供体血液中无HIV-1病毒和丙型肝炎病毒。 2006年,FDA授予APTIMA®HIV-1 RNA定量试剂上市许可证(同时获得专利)。 2007年,FDA批准PROCLEIX®TIGRIS® 系统(首台全自动分子诊断仪器),借助PROCLEIX WNV测定筛查供体血液、器官和组织中的西尼罗病毒(WNV)。 2008年,FDA完全批准在TIGRIS系统中使用PROCLEIX® ULTRIO测定筛查供体血液中的HIV-1、HCV和HBV病毒。 2009年,斥资1.36亿美元现金收购天普尼尔(Tepnel)生命科学公司;该公司位于欧洲,在分子诊断领域迅速崛起,移植诊断业务尤其突出。(美国和欧洲专利当局授予Gen-Probe七项其他领域专利,扩大了其在自动化核酸检测试剂领域的知识产权组合。) 2010年,以6000万美元现金收购Prodesse公司,该公司曾是呼吸道感染疾病分子测试领域的领航者。 2011年,FDA批准了Gen-Probe的APTIMA® HPV测定,这是检验宫颈癌诱发病毒的新型分子检测试剂。 2012年,FDA批准了PROGENSAPCA3试剂以及PANTHER系统。 2012年4月,Hologic以37.2亿美金收购Gen-Probe(每股Gen-Probe股票支付82.75美元,溢价20%)。 2013年4月,Hologic豪洛捷开官微专注关爱女性健康(不过2013年10月2日以后就没有再更新了)。 2016年12月15日,Grifols, S.A.(GRFS)确认收购Hologic(HOLX)在其合资企业中的股份,GRFS将以17亿美元长期贷款及现有账面现金完成收购(共18.5亿美金)。

交易日期 交易人 职位 类型 交易份额 价格
2019-08-04 MacMillan (Stephen P) Chief Executive Officer Sell 81945 49.26
2019-08-04 MacMillan (Stephen P) Chief Executive Officer Sell 112451 48.41
2019-08-04 MacMillan (Stephen P) Chief Executive Officer Buy 215996 22.29
2019-06-02 Valenti (Peter J III) Officer Sell 4545 44.07
2019-03-17 Crawford (Sally W.) Director Buy 12306 20.01
2019-03-17 Crawford (Sally W.) Director Sell 12306 47.61
2019-03-10 Cohn (Benjamin Jordan) Officer Buy 6830 19.86
2019-03-10 Cohn (Benjamin Jordan) Officer Sell 6830 46.70
2019-03-06 Stamoulis (Christiana) Director Buy 2136 --
2019-03-06 Hantson (Ludwig N) Director Buy 2136 --
2019-03-06 Garrett (Scott T) Director Buy 2136 --
2019-03-06 Dockendorff (Charles J) Director Buy 2136 --
2019-03-06 Crawford (Sally W.) Director Buy 2136 --
2019-03-06 Wendell (Amy McBride) Director Buy 2136 --
2019-03-06 Nawana (Namal) Director Buy 2136 --
2019-02-28 Valenti (Peter J III) Officer Sell 4242 47.38
2019-02-01 Bebo (Allison P) Officer Sell 589 43.70
2019-02-01 Griffin (John M) General Counsel Buy 1033 --
2019-02-01 Griffin (John M) General Counsel Buy 1343 --
2018-12-06 Valenti (Peter J III) Officer Sell 4740 42.20
2018-12-03 MacMillan (Stephen P) Chief Executive Officer Sell 3424 43.90
2018-11-30 MacMillan (Stephen P) Chief Executive Officer Sell 8243 44.41
2018-11-30 Valenti (Peter J III) Officer Sell 640 44.41
2018-11-30 Cohn (Benjamin Jordan) Officer Sell 241 44.41
2018-11-30 West (Thomas A) Officer Sell 1011 44.41

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
T. Rowe Price 3764114 1.41% 69796 1.89% 2019-07-31
Fidelity Management and Research Company 13062068 4.87% 10507377 411.30% 2019-03-31
FMR Inc 13264384 4.95% 10709693 419.22% 2019-03-31
Parnassus Investments 15640395 5.83% 100833 0.65% 2019-03-31
BlackRock Inc 18513816 6.91% -189647 -1.01% 2019-03-31
Capital World Investors 25725223 9.60% -1478671 -5.44% 2019-03-31
Capital Research and Management Company 29491759 11.03% -5830534 -16.51% 2019-07-31
Vanguard Group Inc 30722532 11.46% 577303 1.92% 2019-03-31
T. Rowe Price Associates, Inc. 42080238 15.70% -912235 -2.12% 2019-03-31
State Street Corporation 11429962 4.26% 642980 5.96% 2019-03-31
Glenview Capital Management LLC 10758550 4.01% 844507 8.52% 2019-03-31
Capital Research Global Investors 9058420 3.38% -3466269 -27.68% 2019-03-31
Pictet Asset Management S.A. 3804070 1.42% 403835 11.88% 2019-07-31
Geode Capital Management, LLC 4112377 1.53% -3498281 -45.97% 2019-03-31
State Street Global Advisors 4422691 1.65% 15037 0.34% 2019-07-31
Fidelity Management & Research Company 6685197 2.50% 646727 10.71% 2019-07-31
BlackRock Fund Advisors 7224660 2.70% -313471 -4.16% 2019-07-31
Wellington Management Company LLP 7350332 2.74% -2033419 -21.67% 2019-03-31
Fidelity SelectCo, LLC 7692918 2.88% -100000 -1.28% 2019-07-31
Vanguard Investments Australia Ltd 8096529 3.03% 10462 0.13% 2019-07-31
BlackRock Asset Management Canada Ltd 8370298 3.12% 506 0.01% 2019-05-31
BlackRock Japan Co Ltd 3946832 1.47% 3542 0.09% 2019-05-31
Northern Trust Corp 3206982 1.20% 30422 0.96% 2018-12-31
State Street Global Advisors (Aus) Ltd 3046978 1.14% 9920 0.33% 2019-04-30
Northern Trust Investments N A 3206982 1.10% 30422 0.96% 2018-12-31
Jackson National Asset Management LLC 3028586 1.04% -310358 -9.30% 2019-03-31
Pictet Asset Management Ltd 3568867 1.23% -8261 -0.23% 2018-09-30
Pictet Asset Management SA (Junked) 3568867 1.23% -8261 -0.23% 2018-09-30
Victory Capital Management Inc. 3875028 1.33% -1938436 -33.34% 2018-09-30
Amvescap Plc. 4491400 1.54% -235959 -4.99% 2018-09-30
Invesco Capital Management LLC 4109827 1.42% -11387 -0.28% 2018-11-30
Hartford Funds Management Company, LLC 3838052 1.33% -920914 -19.35% 2018-11-30
BlackRock Institutional Trust Company NA 6586790 2.28% -756395 -10.30% 2018-06-30
Wells Fargo & Co 3585262 1.32% -1268483 -26.13% 2018-06-30
Invesco PowerShares Capital Mgmt LLC 3884682 1.43% 1630427 72.33% 2018-06-30
State Street Corp 10790950 3.97% -7146 -0.07% 2018-06-30
Pictet Asset Management SA 3577128 1.32% 180948 5.33% 2018-06-30
Wells Capital Management Inc. 3130102 1.15% -1207294 -27.83% 2018-06-30
Point72 Asset Management, L.P. 2409618 0.89% 1959618 435.47% 2018-06-30
Pioneer Investment Mgmt Inc 2392183 0.88% 870488 57.21% 2018-06-30
Dimensional Fund Advisors, Inc. 2303907 0.85% 2115 0.09% 2018-06-30
D. E. Shaw & Co LP 2654530 0.97% 51558 1.98% 2018-03-31
AllianceBernstein LP 2780374 1.02% -389625 -12.29% 2018-03-31
Two Sigma Investments LLC 2440963 0.89% -387348 -13.70% 2018-03-31
NORGES BANK 1851259 0.67% -659174 -26.26% 2017-12-31
Partner Fund Management LP 1730384 0.63% 1730384 -- 2017-12-31
Segall Bryant & Hamill 1496473 0.54% -38723 -2.52% 2017-12-31
Thrivent Financial For Lutherans 2949045 1.07% -1202060 -28.96% 2017-09-30
Wells Fargo Funds Management LLC 2536384 0.92% 618171 32.23% 2017-11-30
Bank Of New York CO Inc. 1599230 0.57% 403163 33.71% 2017-06-30
Panagora Asset Management Inc 2704195 0.97% 51022 1.92% 2017-06-30
Growth Fund of America Inc 12766895 4.50% -3914405 -23.47% 2015-12-31
Icahn Associates Corp 10234951 3.66% -5589569 -35.32% 2016-04-13
Columbia Mangmt Investment Advisers, LLC 3688767 1.33% 3021792 453.06% 2016-09-30
Lateef Investment Management LP 3509491 1.26% -1135045 -24.44% 2016-09-30
Quantitative Management Associates LLC 3235350 1.16% -323091 -9.08% 2016-09-30
Invesco Advisers, Inc 2836710 1.02% -405922 -12.52% 2016-09-30
Citadel Advisors Llc 2811539 1.01% 1689428 150.56% 2016-09-30
Charles Schwab Investment Management Inc 2588472 0.93% -25741 -0.98% 2016-09-30
TIAA-CREF Investment Management LLC 2445028 0.88% 528437 27.57% 2016-09-30
The Vanguard Group 14397123 1.00% 385267011 -- 1999-11-30
The Growth Fund of America 16551960 1.00% 442930450 0.10% 1999-11-30
BlackRock, Inc 18535439 1.00% 496008348 0.10% 1999-11-30
Carl C. Icahn and related entities 34154879 1.00% 913984562 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Vanguard Mid-Cap Value Index Fund 2407234 0.90% -223985 -8.51% 2019-06-30
Fidelity 4500000 1.68% -100000 -2.17% 2019-06-30
Vanguard 500 Index Fund 5276515 1.97% 64813 1.24% 2019-06-30
American Funds American Balanced Fund 5686479 2.13% -1318521 -18.82% 2019-06-30
Vanguard Mid-Cap Index Fund 6530295 2.44% -465115 -6.65% 2019-06-30
Vanguard Total Stock Market Index Fund 7965982 2.98% 10439 0.13% 2019-06-30
Parnassus Core Equity Fund 8813027 3.30% -270889 -2.98% 2019-06-30
American Funds Growth Fund of Amer 10235000 3.83% -- -- 2019-06-30
T. Rowe Price Mid-Cap Growth Fund 12750000 4.77% -- -- 2019-06-30
T. Rowe Price Mid-Cap Value Fund 4454533 1.67% 588500 15.22% 2019-06-30
American Funds AMCAP Fund 4045600 1.51% -- -- 2019-06-30
CREF Stock Account 3395871 1.27% 784311 30.03% 2019-06-30
MassMutual Select Mid Cap Growth Fund 2417000 0.90% -40000 -1.63% 2019-06-30
Vanguard Institutional Index Fund 2502167 0.94% -15773 -0.63% 2019-06-30
SPDR 2985118 1.12% -8211 -0.27% 2019-07-31
American Funds New Perspective Fund 3070000 1.15% -- -- 2019-06-30
Vanguard Health Care Fund 3078800 1.15% -1849000 -37.52% 2019-03-31
T. Rowe Price Instl Mid-Cap Eq Gr Fd 3117000 1.17% -45018 -1.42% 2019-06-30
T. Rowe Price Health Sciences Fund 3134200 1.17% -105100 -3.24% 2019-06-30
Parnassus Mid Cap Fund 3273516 1.22% -- -- 2019-06-30
Pictet-Robotics 3389317 1.26% 397281 13.28% 2018-09-30
American Funds IS 2573300 0.96% -- -- 2019-03-31
American Funds New Economy Fund 3858000 1.32% -131000 -3.28% 2018-12-31
VA CollegeAmerica New Perspective Fd 3070000 1.05% -- -- 2018-12-31
VA CollegeAmerica AMCAP Fd 5459900 1.87% -1151875 -17.42% 2018-12-31
VA CollegeAmerica The Gr Fd of Amer 10935000 3.75% -- -- 2018-12-31
VA CollegeAmerica The New Economy Fd 3858000 1.32% -131000 -3.28% 2018-12-31
VA CollegeAmerica Amer Blcd Fd 7005000 2.40% 7005000 -- 2018-12-31
T. Rowe Price Value Fund 2625851 0.91% -288279 -9.89% 2018-09-30
Victory Sycamore Established Value Fund 3182275 1.10% -1496025 -31.98% 2018-09-30
Parnassus Endeavor Fund 2500000 0.86% -- -- 2018-10-31
Victory Sycamore Established Value R 4678300 1.72% 348600 8.05% 2018-06-30
American Funds NVIT Growth-Income II 2573300 0.95% -- -- 2018-06-30
Parnassus Endeavor Investor 2500000 0.92% -- -- 2018-07-31
Vanguard Institutional Index I 2637951 0.97% 568 0.02% 2018-07-31
VA CollegeAmerica Grth Fund of Amer 529F 10935000 4.02% 2181100 24.92% 2018-06-30
Parnassus Core Equity Investor 9316091 3.42% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 6846974 2.52% 7038 0.10% 2018-07-31
VA CollegeAmerica Amcap 529F 7195900 2.65% -- -- 2018-06-30
Vanguard Mid Cap Index I 6459648 2.37% 30916 0.48% 2018-07-31
Vanguard 500 Index Inv 4940593 1.82% 476 0.01% 2018-07-31
Vanguard Health Care Inv 4927800 1.81% 541500 12.35% 2018-06-30
T. Rowe Price Mid-Cap Value 4278533 1.57% -21100 -0.49% 2018-06-30
T. Rowe Price Health Sciences 3957700 1.46% -63100 -1.57% 2018-06-30
VA CollegeAmerica New Economy 529F 3546000 1.30% -- -- 2018-06-30
Parnassus Mid-Cap 2885812 1.06% -- -- 2018-07-31
VA CollegeAmerica New Perspective 529E 3070000 1.13% 3070000 -- 2018-06-30
T. Rowe Price Instl Mid-Cap Equity Gr 3040800 1.12% 104800 3.57% 2018-06-30
T. Rowe Price Value 2914130 1.07% -581600 -16.64% 2018-06-30
T. Rowe Price Mid-Cap Growth 12400000 4.56% 125000 1.02% 2018-06-30
American Funds NVIT Growth II 4302130 1.57% -1111268 -20.53% 2018-03-31
JNL/T. Rowe Price Mid-Cap Growth B 2121000 0.77% 139000 7.01% 2017-12-31
Vanguard Mid-Cap Value ETF 2350108 0.85% 25231 1.09% 2018-02-28
PowerShares QQQ ETF 2186538 0.81% 7325 0.34% 2018-01-11
Fidelity Spartan 1569198 0.56% 37751 2.47% 2016-12-31
Health Care Select Sector SPDR 1545755 0.53% 26280 1.73% 2017-02-08
Vanguard Strategic Equity Inv 1473752 0.53% -49400 -3.24% 2016-09-30
VA CollegeAmerica AMCAP 9719600 3.40% -760400 -7.30% 2015-09-30
VA CollegeAmerica New Economy 8174450 2.90% -200000 -2.40% 2015-09-30
American Funds NVIT Growth 7123000 2.50% -790000 -10.00% 2015-09-30
iShares Core S&P Mid-Cap (AU) 4280409 1.60% 2300 -- 2015-11-27
VA CollegeAmerica Fundamental Investors 3565000 1.30% -6440000 -64.40% 2015-09-30
American Funds NVIT Growth-Income Fund 3361300 1.20% -2300000 -40.60% 2015-09-30
Vanguard Extended Market Index Fund 2513414 0.90% 25075 1.00% 2015-10-31
SPDR® S&P MIDCAP 400 ETF 2510389 0.90% 114377 4.80% 2015-10-31
VA CollegeAmerica New Perspective 1990000 0.70% -- -- 2015-09-30
VA CollegeAmerica Growth Fund of America 15219195 5.40% -- -- 2015-09-30

Jay A. Stein Jay A. Stein founded Hologic, Inc. Dr. Stein is Chairman-Emeritus, Chief Technology Officer & SVP at this company. In his past career Dr. Stein held the position of Technical Director-Digital Angiography Group at Advanced Technology Laboratories, Inc. (California). Dr. Stein received a doctorate from Massachusetts Institute of Technology.
Stephen P. MacMillan Mr. Stephen P. MacMillan is an Independent Director at Boston Scientific Corp. and a Chairman, President & Chief Executive Officer at Hologic, Inc. He is on the Board of Directors at Boston Scientific Corp., Advanced Medical Technology Association, United Way of The Battle Creek & Kalamazoo Region and Davidson College. Mr. MacMillan was previously employed as an Independent Director by Alere, Inc., a Chief Executive Officer by Sbiomed LLC, an Independent Director by Texas Instruments Incorporated, a Chairman, President & Chief Executive Officer by Stryker Corp., a Sector Vice President-Global Specialty Operations by Pharmacia Corp., and a President by Johnson & Johnson-Merck Consumer Pharmaceuticals Co. He also served on the board at Domain Surgical, Inc. and Southwest Michigan First (Venture Capital). He received his undergraduate degree from Davidson College.
Karleen Marie Oberton Presently, Karleen Marie Oberton is Chief Financial Officer at Hologic, Inc. and Director & Vice President at Cynosure, Inc. (a subsidiary of Hologic, Inc.). Ms. Oberton is also Member of The Leadership Council. She previously was Senior Audit Manager at Arthur Andersen LLP, Chief Accounting Officer for ImmunoGen, Inc. and Senior Audit Manager at Ernst & Young LLP. She received an undergraduate degree from Merrimack College.
Jay A. Stein Jay A. Stein founded Hologic, Inc. Dr. Stein is Chairman-Emeritus, Chief Technology Officer & SVP at this company. In his past career Dr. Stein held the position of Technical Director-Digital Angiography Group at Advanced Technology Laboratories, Inc. (California). Dr. Stein received a doctorate from Massachusetts Institute of Technology.
Charles J. Dockendorff Charles J. Dockendorff holds the position of Chief Financial Officer & Executive Vice President for Somanetics Corp. He is also on the board of 5 other companies. In the past Mr. Dockendorff occupied the position of Chief Financial Officer & Treasurer for Infrared Industries, Inc., Chief Financial Officer, Treasurer & VP at Epsco, Inc., Chief Financial Officer for Tyco Healthcare (Missouri), Chief Financial Officer & Executive Vice President at Covidien Plc, Chief Financial Officer & Vice President at Aspect Medical Systems, Inc., Chief Financial Officer & Executive Vice President for Covidien LP, Chief Financial Officer for Covidien New Zealand Ltd., Accountant of Arthur Young & Co., Principal at ev3, Inc., Vice President & Controller of Kendall Healthcare Products, Accountant at General Motors Corp. and Accountant at Ernst & Young LLP. Charles J. Dockendorff received an undergraduate degree from the University of Massachusetts and a graduate degree from Bentley University.
Amy A. McBride-Wendell Currently, Amy A. McBride-Wendell occupies the position of Chairman for Por Christo. She is also on the board of Hologic, Inc., Ekso Bionics, Inc. and AxoGen, Inc. In her past career she was Senior Vice President-Strategy at Medtronic Plc SVP-Strategy & Business Development at Covidien New Zealand Ltd. Senior VP-Strategy & Business Development at Covidien Ltd. and Vice President-Business Development & Licensing at Covidien LP (which are all subsidiaries of Medtronic Plc) and VP-Tyco Healthcare Business Development at Kendall Healthcare Products. Amy A. McBride-Wendell received an undergraduate degree from Lawrence Technological University and a graduate degree from the University of Illinois.
Christiana Stamoulis Presently, Christiana Stamoulis is Chief Financial Officer & Executive Vice President of Incyte Corp. She is also on the board of Hologic, Inc. In her past career she held the position of President & Chief Financial Officer of Unum Therapeutics, Inc., Managing Director-Investment Banking Division at Citigroup, Inc., Senior VP-Strategy & Business Development at Vertex Pharmaceuticals, Inc. and Vice President for Goldman Sachs & Co. LLC. Ms. Stamoulis received an undergraduate degree from Massachusetts Institute of Technology and an MBA from MIT Sloan School of Management.
Sally W. Crawford Sally W. Crawford founded Healthsource, Inc. She is on the board of Hologic, Inc. and 6 other companies. In the past she held the position of Chief Operating Officer at Healthsource, Inc., Marketing Director of Matthew Thornton Health Plan, Inc. and Marketing Director of Beacon Health. Ms. Crawford received an undergraduate degree from Smith College and a graduate degree from Boston University.
Elaine S. Ullian Ms. Elaine S. Ullian is on the Board of Directors at Hologic, Inc., Vertex Pharmaceuticals, Inc. and Thermo Fisher Scientific, Inc. Ms. Ullian was previously employed as President & Chief Executive Officer by Boston Medical Center, President & Chief Executive Officer by Boston University Medical Center Hospital, President & Chief Executive Officer by Faulkner Hospital, Inc., President & Chief Executive Officer by Faulkner Corp., an Associate Professor by Boston University, and a Faculty Member by Harvard T.H. Chan School of Public Health. She also served on the board at Valeant Pharmaceuticals International and Thermo Electron Corp. She received her undergraduate degree from Tufts University and a graduate degree from the University of Michigan.
Scott T. Garrett Scott T. Garrett is a businessperson who has been at the helm of 8 different companies. Currently, Mr. Garrett occupies the position of Chairman for ORGENTEC Diagnostika GmbH, Operating Partner at Water Street Healthcare Partners LLC and Chairman at MarketLab, Inc. Mr. Garrett is also on the board of Hologic, Inc., Immucor, Inc. and Genesys Works, Inc. Scott T. Garrett previously occupied the position of Chief Executive Officer at Garrett Capital Advisors LLC, Group Vice President at Baxter International, Inc. President at Baxter Diagnostics, Inc. and Group Vice President at American Hospital Supply Corp. (both are subsidiaries of Baxter International, Inc.), Chairman, President & Chief Executive Officer for Beckman Coulter, Inc., Chairman & Chief Executive Officer for Dade Behring, Inc., Chief Executive Officer for Kendro Laboratory Products LP and President of Dade International, Inc. Scott T. Garrett received an undergraduate degree from Valparaiso University and an MBA from Lake Forest Graduate School of Management.
Michael J. Watts Presently, Michael J. Watts holds the position of VP-Investor Relations & Corporate Communications at Hologic, Inc. and Vice President-Lifecodes & Prodesse at Gen-Probe, Inc. (a subsidiary of Hologic, Inc.). Mr. Watts previously was Principal at Merck & Co., Inc., Director-Investor Relations & Communications at Ligand Pharmaceuticals, Inc. and Strategy Director at Baxter BioScience Corp. Michael J. Watts received an undergraduate degree from Northwestern University and an MBA from the University of California, Los Angeles.
Ludwig N. Hantson Currently, Ludwig N. Hantson holds the position of Chief Executive Officer & Director at Alexion Pharmaceuticals, Inc. Dr. Hantson is also on the board of Hologic, Inc. and Biotechnology Innovation Organization. In his past career Dr. Hantson occupied the position of Principal at Johnson & Johnson, President-BioScience Division at Baxter International, Inc. Chief Executive Officer for Synovis Life Technologies, Inc. and President of Baxter BioScience Corp. (both are subsidiaries of Baxter International, Inc.), President, Chief Executive Officer & Director at Baxalta, Inc., Chief Executive Officer-Pharma North America at Novartis Pharmaceuticals Corp. and Principal at Smith & Nephew NV. Ludwig N. Hantson received a doctorate and a graduate degree from Universit�0�1�0�8 Catholique de Louvain.
Peter J. Valenti Mr. Peter J. Valenti, III MBA, is President-Breast & Skeletal Health Solutions at Hologic, Inc. Mr. Valenti was previously employed as President-North American Vision Care by Bausch & Lomb, Inc., Vice President & General Manager by Covidien, Inc., a Principal by Johnson & Johnson, and a Principal by Procter & Gamble Co. He received his undergraduate degree from the University of Connecticut and an MBA from Cornell University.
Peter J. Valenti Mr. Peter J. Valenti, III MBA, is President-Breast & Skeletal Health Solutions at Hologic, Inc. Mr. Valenti was previously employed as President-North American Vision Care by Bausch & Lomb, Inc., Vice President & General Manager by Covidien, Inc., a Principal by Johnson & Johnson, and a Principal by Procter & Gamble Co. He received his undergraduate degree from the University of Connecticut and an MBA from Cornell University.
Namal Nawana Presently, Namal Nawana holds the position of Chief Executive Officer & Executive Director at Smith & Nephew Plc. Mr. Nawana is also on the board of Hologic, Inc., Advanced Medical Technology Association and AdvaMedDx. He previously was President, Chief Executive Officer & Director at Alere, Inc., Worldwide President at DePuy Synthes Spine, Inc., Vice President at Johnson & Johnson Medical Pty Ltd. (Australia) and Vice President of Johnson & Johnson (New Zealand) Ltd. Namal Nawana received a graduate degree from the University of Adelaide and an MBA from Henley Business School Ltd.
Tracy Campbell Accardi Tracy Campbell Accardi is on the board of Maxim Integrated Products, Inc. In her past career she was Vice President-Global Research & Development at Hologic, Inc., Principal at Johnson & Johnson and Vice President-Global Research & Development at Codman & Shurtleff, Inc. (a subsidiary of Johnson & Johnson), Chief Technology Officer for OmniGuide, Inc., Vice President-Research & Development at Philips Medical Systems, Vice President-Global Research & Development at Covidien Holding, Inc. and Manager-Global Service Technologies at GE Healthcare, Inc. She received an undergraduate degree from Carnegie Mellon University and a graduate degree from Rensselaer Polytechnic Institute.
Stephen P. MacMillan Mr. Stephen P. MacMillan is an Independent Director at Boston Scientific Corp. and a Chairman, President & Chief Executive Officer at Hologic, Inc. He is on the Board of Directors at Boston Scientific Corp., Advanced Medical Technology Association, United Way of The Battle Creek & Kalamazoo Region and Davidson College. Mr. MacMillan was previously employed as an Independent Director by Alere, Inc., a Chief Executive Officer by Sbiomed LLC, an Independent Director by Texas Instruments Incorporated, a Chairman, President & Chief Executive Officer by Stryker Corp., a Sector Vice President-Global Specialty Operations by Pharmacia Corp., and a President by Johnson & Johnson-Merck Consumer Pharmaceuticals Co. He also served on the board at Domain Surgical, Inc. and Southwest Michigan First (Venture Capital). He received his undergraduate degree from Davidson College.
Jan Verstreken Jan Verstreken founded Access Medical SA. He is Regional President-EMEA Region at Hologic, Inc. In the past he was President-APAC Division at Teleflex, Inc.
Stephen P. MacMillan Mr. Stephen P. MacMillan is an Independent Director at Boston Scientific Corp. and a Chairman, President & Chief Executive Officer at Hologic, Inc. He is on the Board of Directors at Boston Scientific Corp., Advanced Medical Technology Association and United Way of The Battle Creek & Kalamazoo Region. Mr. MacMillan was previously employed as an Independent Director by Alere, Inc., a Chief Executive Officer by Sbiomed LLC, an Independent Director by Texas Instruments Incorporated, a Chairman, President & Chief Executive Officer by Stryker Corp., a Sector Vice President-Global Specialty Operations by Pharmacia Corp., and a President by Johnson & Johnson-Merck Consumer Pharmaceuticals Co. He also served on the board at Domain Surgical, Inc. and Southwest Michigan First (Venture Capital). He received his undergraduate degree from Davidson College.
Allison Bebo Allison Bebo occupies the position of Senior Vice President-Human Resources at Hologic, Inc. In her past career Ms. Bebo was District Manager-Northeast Region at Ann Taylor Loft and Vice President-Talent Management at ANN, Inc. Ms. Bebo received an undergraduate degree from the University of California, Los Angeles.
John M. Griffin John M. Griffin is Treasurer & Director at Health Care Volunteers International and General Counsel for Hologic, Inc., Chief Executive Officer for Gen-Probe, Inc., President of Cytyc Corp. and President of Cynosure, Inc. (which are all subsidiaries of Hologic, Inc.). He is also on the board of New England Legal Foundation and Por Christo. In his past career he occupied the position of Vice President & Deputy General Counsel at Covidien Holding, Inc. John M. Griffin received a graduate degree from Harvard Law School and an undergraduate degree from Columbia University.
Patricia K. Dolan Ms. Patricia K. Dolan is a Secretary, Director & Vice President at Cynosure, Inc., a Secretary & Vice President at Hologic, Inc. and a Secretary, Director & Vice President at Cytyc Corp. She is on the Board of Directors at SuperSonic Imagine SA, Cynosure, Inc. and Cytyc Corp.
Ken Daignault Ken Daignault is on the board of Imagin Medical, Inc. and Director-Gynecology Product Development at Hologic, Inc. In the past he was Director-Research & Development at Boston Scientific Corp.
Namal Nawana Presently, Namal Nawana holds the position of Chief Executive Officer & Executive Director at Smith & Nephew Plc. Mr. Nawana is also on the board of Hologic, Inc., Advanced Medical Technology Association and AdvaMedDx. He previously was President, Chief Executive Officer & Director at Alere, Inc., Worldwide President at DePuy Synthes Spine, Inc., Vice President at Johnson & Johnson Medical Pty Ltd. (Australia) and Vice President of Johnson & Johnson (New Zealand) Ltd. Namal Nawana received a graduate degree from the University of Adelaide and an MBA from Henley Business School Ltd.
Marci J. Lerner Currently, Marci J. Lerner occupies the position of Treasurer of Hologic, Inc. and Treasurer, Director & Vice President at Cytyc Corp. and Treasurer, Director & Vice President at Cynosure, Inc. (both are subsidiaries of Hologic, Inc.). Mr. Lerner is also on the board of Hologic UK Finance Ltd.
Amy A. McBride-Wendell Currently, Amy A. McBride-Wendell occupies the position of Chairman for Por Christo. She is also on the board of Hologic, Inc., Ekso Bionics, Inc. and AxoGen, Inc. In her past career she was Senior Vice President-Strategy at Medtronic Plc SVP-Strategy & Business Development at Covidien New Zealand Ltd. Senior VP-Strategy & Business Development at Covidien Ltd. and Vice President-Business Development & Licensing at Covidien LP (which are all subsidiaries of Medtronic Plc) and VP-Tyco Healthcare Business Development at Kendall Healthcare Products. Amy A. McBride-Wendell received an undergraduate degree from Lawrence Technological University and a graduate degree from the University of Illinois.
Benjamin J. Cohn Currently, Benjamin J. Cohn occupies the position of Vice President-Corporate Controller at Hologic, Inc. and Director & Vice President at Cytyc Corp. (a subsidiary of Hologic, Inc.).
Ludwig N. Hantson Currently, Ludwig N. Hantson holds the position of Chief Executive Officer & Director at Alexion Pharmaceuticals, Inc. Dr. Hantson is also on the board of Hologic, Inc. and Biotechnology Innovation Organization. In his past career Dr. Hantson occupied the position of Principal at Johnson & Johnson, President-BioScience Division at Baxter International, Inc. Chief Executive Officer for Synovis Life Technologies, Inc. and President of Baxter BioScience Corp. (both are subsidiaries of Baxter International, Inc.), President, Chief Executive Officer & Director at Baxalta, Inc., Chief Executive Officer-Pharma North America at Novartis Pharmaceuticals Corp. and Principal at Smith & Nephew NV. Ludwig N. Hantson received a doctorate and a graduate degree from Universit�0�1�0�8 Catholique de Louvain.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐